Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Apr;10(4):104533.
doi: 10.1016/j.esmoop.2025.104533. Epub 2025 Apr 1.

Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study

C Marchetti  1 , A Fagotti  2 , R Fruscio  3 , C Cassani  4 , L Incorvaia  5 , M T Perri  6 , C M Sassu  6 , C A Camnasio  4 , E Giudice  6 , A Minucci  7 , M Seca  3 , E Arbustini  4 , L Vertechy  6 , M De Bonis  7 , S M Boccia  6 , D Giannarelli  8 , V Salutari  6 , M Distefano  6 , M G Ferrandina  2 , C Nero  6 , L Musacchio  6 , A Russo  5 , G Scambia  2 , D Lorusso  9
Affiliations
Multicenter Study

Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study

C Marchetti et al. ESMO Open. 2025 Apr.

Abstract

Background: Knowledge about the association between the BRCA1/2 mutation type and location and response to poly (ADP-ribose) polymerase inhibitors (PARPis) as single agent in ovarian cancer is limited. This study aimed to investigate the effectiveness of PARPi based on functional domains (FD) [RING, BRCT, DNA-binding (BD), RAD51-BD] and types (frameshift, missense, nonsense, splicing) of BRCA1/2 gene mutations in ovarian cancer.

Materials and methods: This multicenter real-world study retrospectively enrolled BRCA1/2-mutated ovarian cancer patients receiving olaparib maintenance between January 2010 and December 2022. Data were compared with historical series of patients who did not receive olaparib and analyzed based on the FD involved in BRCA1/2 mutations. Progression-free survival was calculated from the date of the last platinum-based treatment until recurrence or last follow-up.

Results: After a median follow-up of 46 months (range 32-60 months), 140 patients who underwent olaparib maintenance were compared with 128 who did not. PARPi showed efficacy in the overall population. The no-exon 11 patients benefitted more from olaparib than exon 11 patients [hazard ratio (HR) 0.48, 95% confidence interval (CI) 0.25-0.93]. In the BRCA1 group, patients with mutations in RING and BRCT domains had significant benefits from PARPi (HR 0.08, 95% CI 0.01-0.75; HR 0.10, 95% CI 0.02-0.38, respectively). Among BRCA2-mutated patients, RAD51-BD mutations were associated with higher response to olaparib (HR 0.23, 95% CI 0.10-0.52). According to the mutation type, the major effect of PARPi was in the missense group (HR 0.04, 95% CI 0.01-0.31). No patients with p.(Ala1708Glu) in the BRCT domain (BRCA1) receiving PARPi experienced recurring disease in the study period.

Conclusions: BRCA1/2-mutated patients benefit from olaparib, but with variations according to the mutation type and FDs. BRCA1-mutated patients in the RING or BRCT and BRCA2-mutated in the RAD51-BD have the greatest benefit. Patients with missense mutations, especially those with p.(Ala1708Glu), have the most significant advantage from maintenance with PARPi.

Keywords: BRCA mutation; PARP inhibitors; mutation site; mutation type; ovarian cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Progression-free survival according to functional domain in the BRCA1-mutated population (A) and in the BRCA2-mutated population (B). DNA-BD, DNA-binding; PARPi, poly (ADP-ribose) polymerase inhibitors; RAD51-BD, RAD51-binding.
Figure 1
Figure 1
Progression-free survival according to functional domain in the BRCA1-mutated population (A) and in the BRCA2-mutated population (B). DNA-BD, DNA-binding; PARPi, poly (ADP-ribose) polymerase inhibitors; RAD51-BD, RAD51-binding.
Figure 2
Figure 2
Progression-free survival in the overall population according to the type of mutation. PARPi, poly (ADP-ribose) polymerase inhibitors.
See this image and copyright information in PMC

References

    1. Bray F., Laversanne M., Sung H., et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–263. - PubMed
    1. Gurung A., Hung T., Morin J., Gilks C.B. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. Histopathology. 2013;62(1):59–70. - PubMed
    1. Seidman J.D., Horkayne-Szakaly I., Haiba M., Boice C.R., Kurman R.J., Ronnett B.M. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23(1):41–44. - PubMed
    1. Norquist B.M., Harrell M.I., Brady M.F., et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol. 2016;2(4):482–490. - PMC - PubMed
    1. Petrillo M., Marchetti C., De Leo R., et al. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Am J Obstet Gynecol. 2017;217(3):334.e1–334.e9. - PubMed

Publication types